Virenza Rotacaps

Virenza Rotacaps Uses, Dosage, Side Effects, Food Interaction and all others data.

A guanido-neuraminic acid that is used to inhibit neuraminidase.

Virenza Rotacaps, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Virenza Rotacaps has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.

Trade Name Virenza Rotacaps
Availability Prescription only
Generic Zanamivir
Zanamivir Other Names Zanamivir
Related Drugs amantadine, Tamiflu, oseltamivir, Fluzone, Vicks DayQuil Severe Cold & Flu, Xofluza, Coricidin HBP Cold & Flu, Afluria, Fluad, Relenza
Weight 5mg
Type
Formula C12H20N4O7
Weight Average: 332.3098
Monoisotopic: 332.133199014
Protein binding

Zanamivir has limited plasma protein binding (<10%).

Groups Approved, Investigational
Therapeutic Class
Manufacturer Cipla Limited
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Virenza Rotacaps
Virenza Rotacaps

Uses

Virenza Rotacaps is a neuraminidase inhibitor used to treat influenza A and B.

For the prevention and treatment of influenza A and B.

Virenza Rotacaps is also used to associated treatment for these conditions: Flu caused by Influenza

How Virenza Rotacaps works

The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.

Food Interaction

No interactions found.

Virenza Rotacaps Disease Interaction

Major: asthma/COPD

Elimination Route

Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%.

Half Life

2.5-5.1 hours

Clearance

  • 2.5 - 10.9 L/h [Following oral inhalation 10 mg]
  • 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg]
  • 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg]
  • 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg]

Elimination Route

It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Virenza Rotacaps is renally excreted as unchanged drug.

Innovators Monograph

You find simplified version here Virenza Rotacaps

*** Taking medicines without doctor's advice can cause long-term problems.
Share